1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Maryland >
  6. Emalex Biosciences Acquires Psyadon Pharmaceuticals

M&A Deal Summary

Emalex Biosciences Acquires Psyadon Pharmaceuticals

On August 14, 2018, Emalex Biosciences acquired life science company Psyadon Pharmaceuticals

Acquisition Highlights
  • This is Emalex Biosciences’ 1st transaction in the Life Science sector.
  • This is Emalex Biosciences’ 1st transaction in the United States.
  • This is Emalex Biosciences’ 1st transaction in Maryland.

M&A Deal Summary
Date 2018-08-14
Target Psyadon Pharmaceuticals
Sector Life Science
Buyer(s) Emalex Biosciences
Deal Type Add-on Acquisition

Target

Psyadon Pharmaceuticals

Germantown, Maryland, United States
Psyadon Pharmaceuticals, Inc. is a developer, register and marketer of an ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients under 16 years of age.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Emalex Biosciences

Northbrook, Illinois, United States
Category Company
Sector Life Science
DESCRIPTION

Emalex Biosciences, Inc. is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Maryland M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2018 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal